drugset
drugset / Trial / NCT07846280

Study to Assess the Long-term Safety of KN3835 in the Treatment and Retreatment of Flexible/Semi-Flexible Hammertoe (HMT)

NCT07846280 ↗

Phase 3 Not yet recruiting 470 enrolled Endo USA Inc., a Keenova Therapeutics Company
Non-randomizedSequentialDouble-blindTreatment

Summary

The primary purpose of this study is to assess the long-term safety of treatment and retreatment with KN3835 for flexible/semi-flexible HMT.

Timeline

Start
2026-10-11
Primary completion
2028-12
Completion
2028-12

Drugs

EvaluationDrugModalityDoseRoute
Subject KN3835 Unknown — —

Indications

toe, misshapen